Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06441019
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-05-28
Brief Title:
Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma an Open Single-arm Exploratory Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In recent years with the emergence of various new targeted and immunotherapy drugs drug therapy for advanced Hepatocellular carcinoma has also seen continuous breakthroughs The effective rate progression free survival and overall survival of advanced Hepatocellular carcinoma have all significantly improved At present internationally recognized first-line treatments available include atezolizumabbevacizumab TA lenvatinib sorafenib Durvalumabtremelimumab etc However the effective rate of first-line treatment has not exceeded 50 and most patients face difficulties such as drug resistance or treatment failure Second line treatment for Hepatocellular carcinoma still faces many difficulties and challenges The aim of this study is to explore the effectiveness and safety of HAIC combined with TQB2868 and Ramucirumab in second-line treatment of advanced HCC patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None